Psychedelics

Iowa Amendment S-5248 Refines HF 978 Psilocybin Licensing, Oversight and Tax Treatment

In May 2026, Iowa lawmakers introduced amendment S-5248 to HF 978, further reshaping the proposed medical psilocybin regime by broadening eligible conditions, revising the medical controlled substances board’s composition, and clarifying licensing, liability, confidentiality, and tax rules for psilocybin operators. If enacted, this amendment would make the programme more clinically flexible and financially workable for licensed businesses while preserving strict oversight, signalling a more durable state framework for future psilocybin treatment and investment decisions.

6 May 2026, 19:51legis.iowa.govUnited States

New Mexico DOH Proposes Medical Psilocybin Producer and Laboratory Rule 7.35.2 NMAC

New Mexico’s Department of Health has proposed a detailed rule (7.35.2 NMAC) setting permit, testing, traceability, packaging, and enforcement requirements for medical psilocybin producers and laboratories, with a public hearing held on 24 April 2026 and comments taken up to the close of that session. If adopted broadly as drafted, this framework would create a tightly controlled psilocybin supply chain with pharmaceutical-style quality controls, raising compliance and capital requirements for prospective operators but offering clearer risk management and consumer protection for therapeutic psilocybin use in New Mexico.

5 May 2026, 07:21nmhealth.orgUnited States

New Mexico DOH Publishes Public Comments on Draft 7.35.2 NMAC Psilocybin Producer and Laboratory Rule

In April 2026, the New Mexico Department of Health published stakeholder comments on its draft 7.35.2 NMAC psilocybin producer and laboratory rule, consolidating detailed feedback from clinicians and advocacy groups. These comments flag where the final Medical Psilocybin Program regulations may shift—especially around ownership structures, financing safeguards, clinical and guide roles, and operational compliance—so prospective producers, laboratories, and health systems should monitor outcomes closely.

29 Apr 2026, 12:10nmhealth.orgUnited States

Iowa HF 978 Would Create Regulated Medical Psilocybin Programme With Licensing From 2026

Iowa lawmakers are considering HF 978, a bill that would create a tightly regulated medical psilocybin programme with licensed cultivation sites, independent testing laboratories, and registered clinical providers, with licence applications envisaged to open from July 2026 if the bill is enacted. If adopted broadly as drafted, hospitals, clinics, labs, and any businesses seeking to handle psilocybin in Iowa would face new licensing, inventory-control, security, training, and reporting obligations, while employers and insurers would need to monitor evolving non-discrimination and coverage expectations around medically supervised psilocybin use.

25 Apr 2026, 10:47legis.iowa.govUnited States

US Executive Order Accelerates Psychedelic Treatments for Serious Mental Illness

A new US Executive Order directs FDA, DEA, HHS, and the Department of Veterans Affairs to fast‑track psychedelic therapies for serious mental illness, including ibogaine, via priority review vouchers, Right‑to‑Try pathways, Federal‑state partnerships, and expedited rescheduling once products clear Phase 3 trials and win approval. For life sciences sponsors and health systems, this materially lowers policy barriers and accelerates timelines for developing, evidencing, and ultimately prescribing psychedelic‑based treatments, particularly for treatment‑resistant patients and veterans, while signalling future DEA scheduling changes that will reshape compliance strategies.

23 Apr 2026, 14:11whitehouse.govUnited States

Missouri House Passes Public Safety Omnibus HB3068

In April 2026 the Missouri House passed omnibus public-safety bill HB3068 tightening fentanyl and carfentanil trafficking thresholds, broadening drug-induced-death liability, piloting tightly controlled psilocybin use for veterans and first responders, and increasing penalties for damaging critical infrastructure facilities. If enacted in its current form by August 2026, the bill would materially raise criminal and operational risk around potent opioids and critical energy and chemical assets in Missouri while opening a narrow, regulated pathway for psychedelic-assisted therapy research.

23 Apr 2026, 08:27documents.house.mo.govUnited States

Missouri Senate Bill 1682 Proposes Psilocybin Therapy Safe Harbour for Veterans and First Responders

Missouri lawmakers are considering Senate Bill 1682, which would establish a tightly controlled safe harbour for psilocybin-assisted therapy for certain veterans and first responders and broaden the state right-to-try framework to cover Schedule I substances. If enacted, this bill would open a regulated pathway for psilocybin treatment and research in Missouri, signalling a material shift in state controlled-substances policy that mental health providers, hospitals, and emerging psychedelic-therapy businesses would need to track closely.

22 Apr 2026, 19:48senate.mo.govUnited States

Czech Food Inspectorate Flags Muscimol-Containing Psillys Psychedelic Gummies as Dangerous Food

On 13 April 2026, Czech food inspectors classified "Psillys Legal Psychedelic Mushrooms Infused Gummies – Fruit Punch" as a dangerous food after detecting the psychoactive substance muscimol in an official control sample. The case signals that confectionery marketed as "legal psychedelics" in Czechia will face strict enforcement if it contains psychoactive ingredients, elevating compliance and product-liability risks for online sellers and importers.

21 Apr 2026, 13:56potravinynapranyri.czCzechia

South Korea Amends Chemicals Control Act To Ban Promotional Content On Psychedelic Substances

South Korea has adopted a partial amendment to the Chemicals Control Act that, from 7 October 2026, bans labels, advertising and online content which promote intoxicating use of specified “psychedelic” solvents and gases such as toluene, methanol, butane and nitrous oxide. Chemical manufacturers, distributors, brand owners and online platforms serving the Korean market now need to review packaging, marketing and user-facing content for these substances to remove any content that could be interpreted as encouraging inhalant abuse, or face new criminal penalties.

19 Apr 2026, 14:45law.go.krSouth Korea

Iowa Amendment S-5119 Refines HF 978 Medical Psilocybin Licensing and Governance

Iowa’s Health and Human Services Committee has filed amendment S-5119 to HF 978, refining a proposed medical psilocybin regime by reshaping governance, limiting eligibility to adults with PTSD, and shifting key programme milestones into 2027–2029. If enacted, this would create a tightly controlled, state-licensed psilocybin supply chain in Iowa, signalling future compliance obligations and market opportunities for specialised growers, labs, and therapy providers but with no immediate duties until the bill advances.

16 Apr 2026, 10:03legis.iowa.govUnited States

West Virginia Enacts SB 906 To Permit FDA‑Approved Psilocybin Once Federally Rescheduled

West Virginia has enacted SB 906, effective 12 June 2026, amending its controlled substances law so that FDA‑approved, DEA‑rescheduled psilocybin medicines can be lawfully prescribed, distributed, and marketed in the state. This creates a conditional pathway for future medical psilocybin products but leaves psilocybin in Schedule I until specific federal approvals and rescheduling occur, signalling a controlled but significant potential new market for compliant manufacturers and distributors.

15 Apr 2026, 19:30wvlegislature.govUnited States

US DEA Seeks Comment on MDMA Importer Registration for Fisher Clinical Services, Inc.

The US DEA is processing an application to import MDMA for clinical research, with public comments and hearing requests due by May 1, 2026. This highlights the rigorous federal oversight of psychedelic supply chains, where access remains strictly limited to controlled medical trials rather than commercial distribution.

4 Apr 2026, 10:55federalregister.govUnited States

Iowa Legislative Subcommittee Schedules 1 April 2026 Hearing on HF 978 (Psilocybin Bill)

Iowa is advancing legislation to establish a regulated medical psilocybin framework with licensing for production and therapy potentially starting in July 2026. This development signals a shift toward a state-controlled psychedelics market requiring rigorous compliance with production, testing, and inventory standards.

3 Apr 2026, 18:33legis.iowa.govUnited States

US DEA Invites Comments on Importer Registration Application for Research Triangle Institute

The US DEA is reviewing an application to import Schedule I and II controlled substances for research purposes with a comment deadline of May 1, 2026. This administrative process underscores federal control over restricted substance movement and allows domestic manufacturers to monitor and potentially challenge new import registrations.

2 Apr 2026, 17:06federalregister.govUnited States

US DEA Invites Comment on SpecGx LLC Bulk Manufacturer Registration for Schedule I and II Controlled Substances

The US DEA has opened a comment period on an application by SpecGx LLC to register as a bulk manufacturer for a wide range of Schedule I and II controlled substances. This move signals potential shifts in domestic supply chains and quota allocations for highly regulated substances, impacting competitive positioning and market access for existing manufacturers.

27 Mar 2026, 18:17govinfo.govUnited States

South Carolina House Bill 5397 Proposes Schedule I Controls for Substituted Tryptamines

South Carolina introduced legislation in March 2026 to classify a broad range of substituted tryptamines as Schedule I controlled substances. The proposal expands state-level restrictions to include numerous psychedelic analogues, signaling a tightening regulatory environment for synthetic compounds and research chemicals.

27 Mar 2026, 07:52scstatehouse.govUnited States

New Mexico DOH Proposes Rule 7.35.2 NMAC on Medical Psilocybin Producers and Laboratories

New Mexico is establishing a formal regulatory framework for medical psilocybin production and laboratory testing with a public hearing set for April 2026. Prospective operators must prepare for stringent compliance requirements covering traceability, mandatory contaminant testing, and sanitation standards aligned with federal food safety codes.

27 Mar 2026, 06:59nmhealth.orgUnited States

Georgia SB 631 Would Fund FDA-Approved Ibogaine Clinical Trials for Veterans

Georgia introduced legislation to establish state-funded grants for FDA-approved clinical trials using ibogaine for veteran mental health treatments. This initiative reflects a growing state-level shift toward supporting psychedelic research, potentially accelerating the path to market for novel therapeutic substances.

26 Mar 2026, 19:18legis.ga.govUnited States

Minnesota HF4577 Would Establish Psilocybin Therapeutic Use Program and Reschedule Psilocybin

Minnesota has introduced legislation to establish a state-regulated therapeutic psilocybin program and reschedule the substance to Schedule IV by 2027. This proposal creates a structured pathway for medical psychedelic access, requiring stakeholders to navigate rigorous state-level cultivation, testing, and clinical administration standards.

26 Mar 2026, 19:06revisor.mn.govUnited States

South Carolina Bill S1039 Would Add Substituted Tryptamines to Schedule I Controlled Substances

South Carolina introduced legislation in March 2026 to expand its Schedule I controlled substances list by adding a broad category of substituted tryptamines. If enacted, this would criminalize the possession and distribution of numerous psychedelic analogues, requiring immediate portfolio reviews for research, pharmaceutical, or chemical supply operations in the state.

22 Mar 2026, 17:03scstatehouse.govUnited States